NOT a stem cell treatment, but another development in the regulatory backdrop to OCC's (partnered?) ambitions for ATI (and ACI) with the FDA. The first approval of genetically engineered CAR T-Cell therapy by the FDA. Again, the regulatory advancement in the autologous approach, that the FDA's approval history will show it has made dozens of approvals in recent years - the regulatory hurdles for autologous so much lower than allogeneic:
https://european-biotechnology.com/latest-news/fda-approves-cell-therapy-for-solid-tumours/
"TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma...." (Adaptimmune)
Stem Cell Therapy advancements, page-461
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
-0.005(1.16%) |
Mkt cap ! $89.07M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.0¢ | 42.0¢ | $90.9K | 214.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12850 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 24056 | 2 |
View Market Depth
| Last trade - 15.54pm 27/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |